Healthcare provider profile · identity verified

Mark Akselrud, MD

Allopathic & Osteopathic Physicians|Internal Medicine · TAMARAC, FL · NPI 1811999766

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Mark Akselrud, MD received $21.61 in general payments during 2025 across 1 reported records.

ABBVIE INC. accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Linzess by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$21.61

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ABBVIE INC.	Unresolved — no canonical attribution shown	$21.61	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$21.61	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
CREON Normalized: creon	Drug	ABBVIE INC.	$21.61	1	2025
Source payment records 2025-02-20 · ABBVIE INC. · $21.61 · Open Payments source
LINZESS Normalized: linzess	Drug	ABBVIE INC.	$21.61	1	2025
Source payment records 2025-02-20 · ABBVIE INC. · $21.61 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
LINZESS linzess	2025	Linzess	2024	77	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	LINZESS open payments reported associated product	CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608	Linzess · 2024 Exact normalized brand match · 1 Part D row	77	24

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	723	201
Amlodipine Besylate	Amlodipine Besylate	442	125
Losartan Potassium	Losartan Potassium	414	112
Levothyroxine Sodium	Levothyroxine Sodium	411	101
Metformin Hcl	Metformin Hcl	355	94
Gabapentin	Gabapentin	255	78
Pantoprazole Sodium	Pantoprazole Sodium	254	84
Hydralazine Hcl	Hydralazine Hcl	247	71
Eliquis	Apixaban	244	51
Metoprolol Succinate	Metoprolol Succinate	241	74
Rosuvastatin Calcium	Rosuvastatin Calcium	217	60
Metoprolol Tartrate	Metoprolol Tartrate	205	58
Omeprazole	Omeprazole	204	61
Carvedilol	Carvedilol	194	48
Alprazolam	Alprazolam	189	49
Sertraline Hcl	Sertraline Hcl	185	47
Tamsulosin Hcl	Tamsulosin Hcl	164	52
Furosemide	Furosemide	154	45
Potassium Chloride	Potassium Chloride	154	42
Zolpidem Tartrate	Zolpidem Tartrate	153	46
Clopidogrel	Clopidogrel Bisulfate	150	34
Januvia	Sitagliptin Phosphate	141	26
Simvastatin	Simvastatin	133	33
Donepezil Hcl	Donepezil Hcl	121	25
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	120	39
Lisinopril	Lisinopril	119	33
Olmesartan Medoxomil	Olmesartan Medoxomil	118	33
Escitalopram Oxalate	Escitalopram Oxalate	115	23
Hydrochlorothiazide	Hydrochlorothiazide	108	35
Levetiracetam	Levetiracetam	107	16
Ozempic	Semaglutide	104	22
Famotidine	Famotidine	98	39
Azithromycin	Azithromycin	94	76
Meloxicam	Meloxicam	94	31
Allopurinol	Allopurinol	93	25
Quetiapine Fumarate	Quetiapine Fumarate	87	20
Bumetanide	Bumetanide	80	28
Jardiance	Empagliflozin	79	22
Mirtazapine	Mirtazapine	78	19
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	77	28
Labetalol Hcl	Labetalol Hcl	77	21
Linzess	Linaclotide	77	24
Fluticasone Propionate	Fluticasone Propionate	76	31
Nifedipine Er	Nifedipine	75	19
Memantine Hcl	Memantine Hcl	74	11
Prednisone	Prednisone	74	38
Valsartan	Valsartan	72	31
Doxycycline Hyclate	Doxycycline Hyclate	71	39
Trazodone Hcl	Trazodone Hcl	71	23
Finasteride	Finasteride	66	22
Methylprednisolone	Methylprednisolone	65	54
Latanoprost	Latanoprost	64	13
Ezetimibe	Ezetimibe	61	19
Montelukast Sodium	Montelukast Sodium	60	15
Ciprofloxacin Hcl	Ciprofloxacin Hcl	59	46
Pravastatin Sodium	Pravastatin Sodium	59	16
Vascepa	Icosapent Ethyl	59	13
Albuterol Sulfate Hfa	Albuterol Sulfate	58	25
Glimepiride	Glimepiride	58	19
Nystatin	Nystatin	58	14
Duloxetine Hcl	Duloxetine Hcl	55	16
Tizanidine Hcl	Tizanidine Hcl	55	26
Xarelto	Rivaroxaban	55	13
Bisoprolol Fumarate	Bisoprolol Fumarate	53	18
Pioglitazone Hcl	Pioglitazone Hcl	53	16
Alendronate Sodium	Alendronate Sodium	51	15
Spironolactone	Spironolactone	50	19
Clonazepam	Clonazepam	46	18
Vancomycin Hcl	Vancomycin Hcl	45	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	44	15
Entresto	Sacubitril/Valsartan	44	suppressed
Aripiprazole	Aripiprazole	42	suppressed
Cefepime Hcl	Cefepime Hcl	42	suppressed
Rybelsus	Semaglutide	42	11
Tramadol Hcl	Tramadol Hcl	41	25
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	40	13
Atenolol	Atenolol	39	13
Meclizine Hcl	Meclizine Hcl	39	24
Bupropion Xl	Bupropion Hcl	38	13
Isosorbide Mononitrate Er	Isosorbide Mononitrate	38	11
Lactulose	Lactulose	38	17
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	38	11
Hydroxyzine Hcl	Hydroxyzine Hcl	37	12
Sodium Chloride	0.9 % Sodium Chloride	37	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	37	21
Midodrine Hcl	Midodrine Hcl	36	15
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	36	suppressed
Baclofen	Baclofen	35	suppressed
Icosapent Ethyl	Icosapent Ethyl	35	11
Celecoxib	Celecoxib	34	23
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	34	11
Fenofibrate	Fenofibrate	34	suppressed
Divalproex Sodium	Divalproex Sodium	33	suppressed
Levofloxacin	Levofloxacin	33	27
Buspirone Hcl	Buspirone Hcl	32	11
Citalopram Hbr	Citalopram Hydrobromide	30	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	29	12
Tradjenta	Linagliptin	29	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	28	suppressed
Mounjaro	Tirzepatide	27	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	27	suppressed
Novolog Flexpen	Insulin Aspart	27	suppressed
Pregabalin	Pregabalin	27	suppressed
Clonidine Hcl	Clonidine Hcl	26	suppressed
Farxiga	Dapagliflozin Propanediol	26	suppressed
Temazepam	Temazepam	26	11
Dicyclomine Hcl	Dicyclomine Hcl	25	15
Ondansetron Hcl	Ondansetron Hcl	25	16
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	24	19
Nitroglycerin Patch	Nitroglycerin	23	suppressed
Amiodarone Hcl	Amiodarone Hcl	22	suppressed
Glipizide	Glipizide	22	suppressed
Meropenem	Meropenem	22	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	22	suppressed
Lubiprostone	Lubiprostone	21	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	21	suppressed
Calcium Acetate	Calcium Acetate	20	suppressed
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	20	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	20	suppressed
Lovastatin	Lovastatin	20	suppressed
Sildenafil Citrate	Sildenafil Citrate	20	suppressed
Xifaxan	Rifaximin	20	suppressed
Nebivolol Hcl	Nebivolol Hcl	19	suppressed
Santyl	Collagenase Clostridium Hist.	19	suppressed
Topiramate	Topiramate	19	suppressed
Warfarin Sodium	Warfarin Sodium	19	suppressed
Fluconazole	Fluconazole	18	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	18	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	18	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	18	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	18	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	17	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	17	suppressed
Paroxetine Hcl	Paroxetine Hcl	17	suppressed
Telmisartan	Telmisartan	17	suppressed
Cefdinir	Cefdinir	16	13
Fetroja	Cefiderocol Sulfate Tosylate	16	suppressed
Irbesartan	Irbesartan	16	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	16	suppressed
Mupirocin	Mupirocin	16	12
Timolol Maleate	Timolol Maleate	16	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Budesonide	Budesonide	15	suppressed
Cefuroxime	Cefuroxime Axetil	15	12
Diazepam	Diazepam	15	suppressed
Ipratropium Bromide	Ipratropium Bromide	15	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	15	suppressed
Olmesartan-Amlodipine-Hctz	Olmesartan/Amlodipin/Hcthiazid	15	suppressed
Piperacillin-Tazobactam	Piperacillin Sodium/Tazobactam	15	suppressed
Diclofenac Sodium	Diclofenac Sodium	14	suppressed
Hydrocortisone	Hydrocortisone	14	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	14	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	14	suppressed
Symbicort	Budesonide/Formoterol Fumarate	14	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	14	suppressed
Acyclovir	Acyclovir	13	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	13	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	13	suppressed
Metformin Hcl Er	Metformin Hcl	13	suppressed
Oxcarbazepine	Oxcarbazepine	13	suppressed
Sucralfate	Sucralfate	13	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	13	suppressed
Tresiba Flextouch U-100	Insulin Degludec	13	suppressed
Ventolin Hfa	Albuterol Sulfate	13	suppressed
Amoxicillin	Amoxicillin	12	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	12	suppressed
Humalog	Insulin Lispro	12	suppressed
Humalog Kwikpen U-100	Insulin Lispro	12	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	12	suppressed
Nuedexta	Dextromethorphan Hbr/Quinidine	12	suppressed
Olanzapine	Olanzapine	12	suppressed
Propranolol Hcl	Propranolol Hcl	12	suppressed
Cilostazol	Cilostazol	11	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	11	suppressed
Flecainide Acetate	Flecainide Acetate	11	suppressed
Humalog Mix 75-25 Kwikpen	Insulin Lispro Protamin/Lispro	11	suppressed
Humulin R	Insulin Regular, Human	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$21.61 · 1 records	ABBVIE INC.	CREON, LINZESS	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Linzess play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error